Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06669234 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults

StatusCompleted
PhasePhase 1
Started2025-03-06
View on ClinicalTrials.gov ↗

Amendment history

2026-10-01
Trial completed
2026-02-19
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v3
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 40→confirmed 56
Study sitesdetails revised at 1 of 1 site
2025-11-20
Study Identification, Study Status, Contacts/Locations v2
Study sitesdetails revised at 1 of 1 site
2025-03-14
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2026-08-06→2026-07-30
Completion date2026-08-06→2026-07-30
Start dateestimated 2025-03-11→confirmed 2025-03-06
Study sites0→1
2024-10-30
Original filing
Regeneron
148 trials monitored
See 16 trials at risk
This clinical research trial will evaluate the safety and tolerability of an experimental drug, ALN-F1202, in healthy participants. The purpose of this trial is to learn about how safe and tolerable the experimental drug is. The trial is looking at several other research questions, including: * What side effects may happen from taking the experimental drug? * How much experimental drug is in the blood at different times? * Whether the body makes antibodies against the experimental drug (which could make the drug less effective or could lead to side effects). * What is the best dose of the experimental drug?
Trial Details
NCT Number NCT06669234
Lead Sponsor Regeneron Pharmaceuticals
Conditions Healthy Volunteer
Enrollment 56 participants
Start Date 2025-03-06
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-08-04 (estimated)
Updated on ClinicalTrials.gov 2026-09-30